Related Experiment Video
Updated: Jul 18, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Buprenorphine and HIV primary care: report of a forum for collaborative HIV research workshop
1Forum for Collaborative HIV Research, George Washington University, Washington, DC, USA. vmiller@gwu.edu
Abstract:
On 3-4 June 2004, in Washington, DC, the Forum for Collaborative HIV Research convened experts from academia, community and private practices, US government agencies, and industry to develop recommendations for increased uptake of buprenorphine integrated into human immunodeficiency virus (HIV) primary care, with special emphasis on Ryan White CARE Act-funded programs. Workshop participants evaluated knowledge gaps requiring research; barriers to integration at the patient, clinic, and systems level; policy and financing issues; and program impacts. Recommendations were developed for training, including medical school and post-medical school training of clinical teams as well as training of patients; for improving programs and services, including integration of opioid dependence and HIV infection into chronic disease models, providing flexible access to core and support services, and monitoring and evaluation of programs; for changes in policy supportive of program and services goals; for financing buprenorphine treatment by use of existing models of integrated treatment and merging funding streams at the local level; and for addressing research gaps, including cost-effectiveness research.
Related Concept Videos
Retroviruses
Subviral Agents
Chronic Pancreatitis II: Collaborative Care
Assessment:
Drug Dependence
Retrovirus Life Cycles
Clinical Trials: Overview

